Triamcinolone (Optional)

DRUG2 trials

Sponsors

Eli Lilly and Company, Research Insight LLC

Conditions

Atopic DermatitisPost Cataract Surgery

Phase 2

A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

CompletedNCT02576938

Eli Lilly and CompanyAtopic Dermatitis

Start: 2016-02-29End: 2017-03-31Updated: 2020-06-17

Phase 4

The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)

Not yet recruitingNCT07276802

Research Insight LLCPost Cataract Surgery

Start: 2026-04-01End: 2027-01-31Target: 40Updated: 2026-03-31

Related Papers

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

JEADV Clinical Practice2025-09-24

Safety of baricitinib for the treatment of atopic dermatitis over a median of 1.6 years and up to 3.9 years of treatment: an updated integrated analysis of eight clinical trials.

2023-12-0132 citations

Pooled Analysis of Baricitinib Tolerability in Patients With Atopic Dermatitis in Relation to Acne, Headache, and Gastrointestinal Events From 8 Clinical Trials

Dermatitis2023-02-076 citations

Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials.

2022-10-185 citations

Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.

2021-04-0726 citations